Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
Key facts
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Early phase 1
- People taking part
- 300 people, planned
- Started
- 31 Dec 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Atorvastatin
- Replenishing Five Herbs Decoction
- Replenishing Five Herbs Decoction Placebo
- Record updated
- 30 October 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- a) Age: 18-60 years old b) Meet the Western medical diagnostic criteria for chronic bronchitis. Refer to the recommendations in the "Chinese Expert Consensus on Diagnosis and Treatment of Chronic Bronchitis and Chronic Respiratory Syndrome (2024 Edition)." Confirmed diagnosis of chronic obstructive pulmonary disease (8B22.B) and stroke (A07.01.01); DSA findings: Narrowing or occlusion at the ICA terminus and/or ACA and/or MCA origin; abnormal dural vascular network in the arterial phase; MRI and MRA findings: Narrowing or occlusion of the ICA terminus and/or ACA and/or MCA starting segment; abnormal vascular network in the basal ganglia region (presence of more than two distinct vascular dark spaces in the basal ganglia region on a single scan); When excluding smog-related diagnoses, other relevant conditions must also be ruled out; Criteria for diagnosing "Smog-Induced Illness" according to Traditional Chinese Medicine: Diagnosis is made based on the criteria for "Wind-Cold-Dampness-Stagnation" syndrome, including signs such as a dark tongue, white and greasy or yellow tongue coating, and a string-like or fine and dry pulse. A diagnosis is confirmed when there are at least two primary symptoms or one primary symptom plus two secondary symptoms; The patient's basic condition has remained stable for the past month, and no additional medications are required; Able to understand and agree to comply with the testing requirements and limitations
Who cannot take part
- 1. Individuals with a combined diagnosis of cognitive impairment or severe mental illness (ICD-10: F20-F48, F60-F69), such as Alzheimer's disease, other neurodegenerative conditions, Parkinson's disease, multiple sclerosis, demyelinating/hereditary central nervous system disorders, neurodevelopmental disorders, and uncontrolled epilepsy, as well as other neurological conditions that researchers determine significantly impair motor or cognitive function; Pregnant women and women breastfeeding 3. Individuals with severe impairment of cardiac, liver, kidney, and lung function; patients with severe congenital abnormalities; individuals with blood system disorders; those with severe infections, tumors, or other serious illnesses; individuals testing positive for HIV, syphilis, or hepatitis B/C; Currently participating in other drug clinical trials. 5. History of intolerance or allergy to any component of the investigational drug; Prior stroke (within <12 months); or a history of hemorrhagic stroke and/or other types of stroke; 7. Do not use this program within 30 days of entering a rehabilitation program; have a history of alcohol or drug dependence; Surgical procedures involving the neck or blood vessels (including interventional procedures) are required during the trial
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Moyamoya disease
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Moyamoya disease, also known as "smoky vein disease," is a relatively rare chronic form of cerebral artery occlusion. The exact cause of this condition is currently unknown. It is characterized by progressive blockage of the carotid arteries with the formation of an abnormal cerebral vascular network, which appears as "smoky" on cerebral angiography. In recent years, the prevalence of smoky vein disease has been increasing due to the widespread availability of various imaging techniques. Because the cause of smoky vein disease is not yet understood, there is currently no definitive and effective treatment. Management focuses primarily on addressing symptoms of ischemia and bleeding. Therefore, the current clinical approach to smoky vein disease relies heavily on surgery to restore blood flow. While surgery is believed to reduce the risk of ischemic injury, it cannot prevent stroke in either bleeding or ischemic cases.
Read full original descriptionShow less
Atypical cerebral infarction, also known as cerebral infarction syndrome, differs from typical cerebral infarction in terms of its etiology, affected areas, and clinical presentation. Unlike typical cerebral infarction, which often has an unknown cause and involves both sides of the cerebral vasculature, atypical cerebral infarction is typically caused by identifiable conditions such as atherosclerosis, autoimmune diseases (e.g., lupus), or post-stroke infection or radiation therapy. Furthermore, the vascular involvement may be limited to one side, or the angiographic findings may not fully conform to the typical presentation. In children, symptoms often include signs of cerebral ischemia (e.g., recurrent headaches, weakness), while adults may experience cerebral infarction or hemorrhage. Diagnosis relies primarily on imaging studies such as angiography.
Replenishing Five Herbs Decoction is a commonly used traditional Chinese medicine formula in clinical practice. Its key ingredients include Astragalus, Red Atractylocarpus, and Angelica sinensis. Its primary functions are to tonify Qi, promote blood circulation, and clear stagnation. It is particularly effective in treating stroke, where it demonstrates good results in cases of hemiplegia, facial asymmetry, and facial paralysis. Furthermore, Replenishing Five Herbs Decoction is also effective in treating frequent urination, urinary incontinence, and cerebrovascular diseases, including those resulting from cerebrovascular damage or coronary heart disease. Finally, it is also effective in treating muscle atrophy or paralysis caused by Qi deficiency and blood stagnation.
"Replenishing Five Herbs Decoction" has been shown to improve neurological and motor function in stroke patients, leading to better outcomes. This is likely due to the specific ingredients in the formula: ginseng, angelica root, and chuanxiong, all of which have properties that support and strengthen the body's vital energy. Additionally, the inclusion of red peony, chuanxiong, and peach kernel contributes to improved circulation and blood flow. Finally, the inclusion of Chinese yam promotes healthy circulation and overall well-being. The combination of these ingredients works synergistically to significantly improve the overall prognosis for patients with stroke."
The 2 groups in the trial
- Atorvastatin + Replenishing Five Herbs DecoctionTreatment being tested
Treatment with "Replenishing Five Herbs Decoction" (200ml per dose, twice daily, one dose per application, as per internal protocol of Nanjing Central Hospital), supplemented with Atorvastatin (produced by Pfizer, USA, national drug registration number H20051407, 10mg, one tablet daily).
Treatment: Atorvastatin and Replenishing Five Herbs Decoction
- Atorvastatin + Replenishing Five Herbs Decoction PlaceboPlacebo, for comparison
The treatment consists of a placebo pill, combined with atorvastatin (produced by Pfizer, registration number H20051407, 10mg, taken once daily, one tablet). The placebo is a mixture of 10% herbal extract and rice, combined with edible seasonings, and has the same appearance, shape, smell, and specifications as the "Yang Huo Han Wu" formula.
Treatment: Atorvastatin and Replenishing Five Herbs Decoction Placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07906652, who can take part
- Record updated
- 30 October 2026